While Phathom Pharmaceuticals Inc has overperformed by 0.79%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PHAT rose by 89.16%, with highs and lows ranging from $16.45 to $2.21, whereas the simple moving average jumped by 64.24% in the last 200 days.
On December 12, 2025, Raymond James started tracking Phathom Pharmaceuticals Inc (NASDAQ: PHAT) recommending Strong Buy. A report published by Barclays on December 09, 2025, Initiated its previous ‘Equal Weight’ rating for PHAT. Cantor Fitzgerald also rated PHAT shares as ‘Overweight’, setting a target price of $23 on the company’s shares in an initiating report dated February 14, 2025. Stifel Initiated an Buy rating on May 03, 2024, and assigned a price target of $24. Needham resumed its ‘Buy’ rating for PHAT, as published in its report on January 05, 2024. H.C. Wainwright’s report from August 09, 2023 suggests a price prediction of $28 for PHAT shares, giving the stock a ‘Buy’ rating. Evercore ISI also rated the stock as ‘Outperform’.
Analysis of Phathom Pharmaceuticals Inc (PHAT)
Further, the quarter-over-quarter increase in sales is 202.74%, showing a positive trend in the upcoming months.
Phathom Pharmaceuticals Inc’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. Taking into account the quick ratio of the company, currently set at 2.19, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and PHAT is registering an average volume of 1.06M. On a monthly basis, the volatility of the stock is set at 5.32%, whereas on a weekly basis, it is put at 5.98%, with a gain of 5.57% over the past seven days. Furthermore, long-term investors anticipate a median target price of $22.90, showing growth from the present price of $15.36, which can serve as yet another indication of whether PHAT is worth investing in or should be passed over.
How Do You Analyze Phathom Pharmaceuticals Inc Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 41.86%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 50.71% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
